Drug Trial Radar · NCT07904728
Treating Contact Lens Discomfort With Cyclosporine 0.1% Ophthalmic Solution
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 25, 2026
Primary completion
Mar 15, 2027
Study completion Apr 15, 2027
Sponsor
- Lead sponsor
- Ocular Aesthetics, LLC dba Ocular Clinical TrialsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Harrow Eye, LLC
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Of the 140 million contact lens (CL) wearers worldwide, most wear soft contact lenses. Despite major improvements in contact lens care, nearly 20% of wearers stop using lenses, with contact lens discomfort (CLD) being the main reason. This study aims to determine whether VEVYE, a water-free 0.1% cyclosporine ophthalmic solution indicated for the treatment of DED, can improve contact lens comfort in people with dry eye disease.
Conditions
- Dry Eye Disease (DED)
- Contact Lens Discomfort (CLD)
Interventions
Cyclosporine 0.1% Ophthalmic SolutionDrug
Participants will be treated with VEVYE (water-free cyclosporine 0.1% ophthalmic solution) twice per day in each eye before and after contact lens use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)Time frame: Baseline compared to 12 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ocular Clinical Trials
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.